Sergei Nicolaevich Bondarenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sergei Nicolaevich Bondarenko has a total of 212 co-authors. Here are the top co-authors by number of shared publications:
- Aleksander Dmitrievich Kulagin
Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I. P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia
14 shared publications - Ivan Sergeevich Moiseev
Pavlov First Saint Petersburg State Medical University
14 shared publications - Lyudmila Stepanovna Zubarovskaya
I.P. Pavlov First Saint Petersburg State Medical University of Ministry of Health of the Russian Federation
10 shared publications - Tatiana Leonidovna Gindina
RM Gorbacheva Research Institute, Pavlov University, 6/8 L’va Tolstogo ul., Saint Petersburg, Russian Federation, 197022
9 shared publications - Yulia Yurievna Vlasova
Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation, I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia
7 shared publications - Boris V. Afanasyev
Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, First Pavlov State Medical University of St. Petersburg, Ministry of Health of Russia
6 shared publications
Latest Publications
- 25 March 2026
- Published by Wiley in European Journal of Haematology
- Vol. 117 (1) , 192-199
Secondary Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome Following Allo‐ HCT : Features, Outcomes, and Risk Stratification
Background: Secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome (sHLH/MAS) is a rare but highly fatal complication after allogeneic hematopoietic cell transplantation (allo‐HCT), frequently diagnosed under conditions of clinical uncertainty. We aimed to characterize post‐transplant sHLH/MAS and to identify clinically accessible factors associated with early mortality. Methods: We retrospectively analyzed adult patients who developed sHLH/MAS after allo‐HCT between 2018 and 2025. Inclusion required an HScore ≥ 169. Overall survival within 60 days from sHLH/MAS onset was the primary endpoint. Clinical and laboratory variables were evaluated using Cox proportional‐hazards models, and patients were stratified according to the number of adverse prognostic factors identified. Results: Seventy‐two patients met inclusion criteria. Median time from allo‐HCT to sHLH/MAS onset was 22 days. Sixty‐day overall survival was poor. In univariable and multivariable analyses, vasopressor‐dependent sepsis (HR 7.77, p < 0.001) and ferritin > 15 000 μg/L (HR 3.48, p = 0.002) were independently associated with early mortality. Stratification based on these two factors separated patients into low‐, intermediate‐, and high‐risk groups with 60‐day survival of 92%, 52%, and 9%, respectively ( p < 0.001). Conclusions: Post‐transplant sHLH/MAS is associated with extremely high early mortality. Vasopressor‐dependent sepsis and extreme hyperferritinemia identify patients at particularly high risk. These findings require confirmation in independent cohorts.
- 25 March 2026
- Published by Wiley in European Journal of Haematology
- Vol. 117 (1) , 192-199
Secondary Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome Following Allo‐ HCT : Features, Outcomes, and Risk Stratification
Background: Secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome (sHLH/MAS) is a rare but highly fatal complication after allogeneic hematopoietic cell transplantation (allo‐HCT), frequently diagnosed under conditions of clinical uncertainty. We aimed to characterize post‐transplant sHLH/MAS and to identify clinically accessible factors associated with early mortality. Methods: We retrospectively analyzed adult patients who developed sHLH/MAS after allo‐HCT between 2018 and 2025. Inclusion required an HScore ≥ 169. Overall survival within 60 days from sHLH/MAS onset was the primary endpoint. Clinical and laboratory variables were evaluated using Cox proportional‐hazards models, and patients were stratified according to the number of adverse prognostic factors identified. Results: Seventy‐two patients met inclusion criteria. Median time from allo‐HCT to sHLH/MAS onset was 22 days. Sixty‐day overall survival was poor. In univariable and multivariable analyses, vasopressor‐dependent sepsis (HR 7.77, p < 0.001) and ferritin > 15 000 μg/L (HR 3.48, p = 0.002) were independently associated with early mortality. Stratification based on these two factors separated patients into low‐, intermediate‐, and high‐risk groups with 60‐day survival of 92%, 52%, and 9%, respectively ( p < 0.001). Conclusions: Post‐transplant sHLH/MAS is associated with extremely high early mortality. Vasopressor‐dependent sepsis and extreme hyperferritinemia identify patients at particularly high risk. These findings require confirmation in independent cohorts.
- Open Access
- 12 January 2026
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (1) , 3
Long-term follow-up of predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia in the phase 3 COMMODORE trial
To evaluate the long-term efficacy and safety of gilteritinib compared with salvage chemotherapy (SC) in patients with relapsed/refractory FMS -like tyrosine kinase 3 ( FLT3 )-mutated acute myeloid leukemia (AML). In the phase 3 COMMODORE (NCT03182244) trial, patients with relapsed/refractory FLT3 -mutated AML from China, Russia, Singapore, Thailand, and Malaysia were randomized to gilteritinib (120 mg/day) or SC. The long-term follow-up included assessments every 3 months for a maximum of 3 years from the end-of-treatment visit. The primary endpoint was overall survival (OS). Secondary endpoints included event-free survival (EFS), complete remission (CR) rate, hematopoietic stem cell transplantation (HSCT) rate, and transfusion maintenance and conversion rates. Overall, 276 patients (gilteritinib, n = 137; SC, n = 139) completed the long-term follow-up. Most (88.0%) patients were Asian. The median (95% confidence interval [CI]) OS was longer with gilteritinib versus SC (10.3 [8.8, 12.7] vs 5.4 [4.1, 8.1] months, respectively; hazard ratio [HR; 95% CI], 0.612 [0.451, 0.832]), with a median follow-up of 34.6 months. The median (95% CI) EFS was longer with gilteritinib versus SC (2.1 [< 0.1, 3.2] vs 0.6 [0.2, 1.2] months, respectively; HR [95% CI], 0.589 [0.438, 0.792]). The CR rate was 20.4% and 11.5% in the gilteritinib and SC arms, respectively. During the entire study period, 22.6% and 7.9% of patients in the gilteritinib and SC arms underwent HSCT, respectively; 18.2% of patients in the gilteritinib arm received on-study HSCT. No new safety concerns were identified. Long-term gilteritinib treatment improved clinical outcomes compared with SC and was well-tolerated in a predominantly Asian population with relapsed/refractory FLT3 -mutated AML.
- 12 January 2026
- Published by Springer Nature in Annals of Hematology
- Vol. 105 (1) , 3
Open AccessLong-term follow-up of predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia in the phase 3 COMMODORE trial
To evaluate the long-term efficacy and safety of gilteritinib compared with salvage chemotherapy (SC) in patients with relapsed/refractory FMS -like tyrosine kinase 3 ( FLT3 )-mutated acute myeloid leukemia (AML). In the phase 3 COMMODORE (NCT03182244) trial, patients with relapsed/refractory FLT3 -mutated AML from China, Russia, Singapore, Thailand, and Malaysia were randomized to gilteritinib (120 mg/day) or SC. The long-term follow-up included assessments every 3 months for a maximum of 3 years from the end-of-treatment visit. The primary endpoint was overall survival (OS). Secondary endpoints included event-free survival (EFS), complete remission (CR) rate, hematopoietic stem cell transplantation (HSCT) rate, and transfusion maintenance and conversion rates. Overall, 276 patients (gilteritinib, n = 137; SC, n = 139) completed the long-term follow-up. Most (88.0%) patients were Asian. The median (95% confidence interval [CI]) OS was longer with gilteritinib versus SC (10.3 [8.8, 12.7] vs 5.4 [4.1, 8.1] months, respectively; hazard ratio [HR; 95% CI], 0.612 [0.451, 0.832]), with a median follow-up of 34.6 months. The median (95% CI) EFS was longer with gilteritinib versus SC (2.1 [< 0.1, 3.2] vs 0.6 [0.2, 1.2] months, respectively; HR [95% CI], 0.589 [0.438, 0.792]). The CR rate was 20.4% and 11.5% in the gilteritinib and SC arms, respectively. During the entire study period, 22.6% and 7.9% of patients in the gilteritinib and SC arms underwent HSCT, respectively; 18.2% of patients in the gilteritinib arm received on-study HSCT. No new safety concerns were identified. Long-term gilteritinib treatment improved clinical outcomes compared with SC and was well-tolerated in a predominantly Asian population with relapsed/refractory FLT3 -mutated AML.
- Open Access
- 1 July 2025
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 18 (3) , 257-269
Comparative Assessment of Long-Term Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors Registered in the Russian and International Databases for Hematologic Diseases
BACKGROUND. In recent years, the number of allogeneic hematopoietic stem cell transplantations (allo-HSCT) has continued to rise due to the ongoing improvement of transplantation technologies and rapid growth of bone marrow donor registries. Clinical outcomes of allo-HSCT depend on many factors including ethnic matching of patients and donors. There is evidence on a higher efficacy of allo-HSCT from the national registry donors compared with the donors from international registries. AIM. To assess the efficacy of allo-HSCT from the Russian and foreign donors. MATERIALS & METHODS. This retrospective clinical study enrolled 585 patients with various hematologic diseases. In the RM Gorbacheva Research Institute, in the period from 2010 to 2019, all patients received allo-HSCT from 9/10 or 10/10 HLA-matched unrelated donors from the Russian (n = 141) and international (n = 444) registries. In the early post-transplant period, cyclophosphamide was administered to all patients to prevent the graft-versus-host disease (GVHD). Paired analysis was carried out in two groups of patients formed and balanced according to the following criteria: age, disease variant, conditioning regimen intensity, graft source, the number of allo-HSCT recipients out of remission, and the year of transplantation. The median follow-up in the total group was 17 months (range 1–74 months). RESULTS. The outcomes of allo-HSCT from the Russian and international donors appeared to be compatible: the 5-year overall survival was 64 % and 62 %, respectively (p = 0.19), the 5-year event-free survival was 57 % and 43 % (p = 0.14), the transplant mortality was 17 % and 18 % (p = 0.62), and the cumulative relapse incidence was 12 % and 20 %, respectively (p = 0.08). The paired analysis yielded similar results in both groups for all the above mentioned end points. The risks of acute as well as chronic GVHD appeared to be the same. CONCLUSION. The long-terms outcomes of allo-HSCT from the Russian and foreign donors proved to be compatible. Further development of the Federal Bone Marrow Donor Registry will provide availability and affordability of allo-HSCT for more citizens of the Russian Federation. This remains an issue of current concern because of the challenges of logistics, financing, and a longer interval between the donor search through international registries and allo-HSCT performance.
- 1 July 2025
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 18 (3) , 257-269
Open AccessComparative Assessment of Long-Term Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors Registered in the Russian and International Databases for Hematologic Diseases
BACKGROUND. In recent years, the number of allogeneic hematopoietic stem cell transplantations (allo-HSCT) has continued to rise due to the ongoing improvement of transplantation technologies and rapid growth of bone marrow donor registries. Clinical outcomes of allo-HSCT depend on many factors including ethnic matching of patients and donors. There is evidence on a higher efficacy of allo-HSCT from the national registry donors compared with the donors from international registries. AIM. To assess the efficacy of allo-HSCT from the Russian and foreign donors. MATERIALS & METHODS. This retrospective clinical study enrolled 585 patients with various hematologic diseases. In the RM Gorbacheva Research Institute, in the period from 2010 to 2019, all patients received allo-HSCT from 9/10 or 10/10 HLA-matched unrelated donors from the Russian (n = 141) and international (n = 444) registries. In the early post-transplant period, cyclophosphamide was administered to all patients to prevent the graft-versus-host disease (GVHD). Paired analysis was carried out in two groups of patients formed and balanced according to the following criteria: age, disease variant, conditioning regimen intensity, graft source, the number of allo-HSCT recipients out of remission, and the year of transplantation. The median follow-up in the total group was 17 months (range 1–74 months). RESULTS. The outcomes of allo-HSCT from the Russian and international donors appeared to be compatible: the 5-year overall survival was 64 % and 62 %, respectively (p = 0.19), the 5-year event-free survival was 57 % and 43 % (p = 0.14), the transplant mortality was 17 % and 18 % (p = 0.62), and the cumulative relapse incidence was 12 % and 20 %, respectively (p = 0.08). The paired analysis yielded similar results in both groups for all the above mentioned end points. The risks of acute as well as chronic GVHD appeared to be the same. CONCLUSION. The long-terms outcomes of allo-HSCT from the Russian and foreign donors proved to be compatible. Further development of the Federal Bone Marrow Donor Registry will provide availability and affordability of allo-HSCT for more citizens of the Russian Federation. This remains an issue of current concern because of the challenges of logistics, financing, and a longer interval between the donor search through international registries and allo-HSCT performance.
- Open Access
- 19 March 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (1) , 114-121
How to reduce the risk of primary engraftment failure after haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia?
Background. Haploidentical hematopoietic stem cell transplantation (haplo‑HSCT) represents an important alternative for patients with acute myeloid leukemia (AML) who lack an HLA‑matched donor. However, the high incidence of primary graft failure remains a significant challenge. Optimizing transplantation strategies, including the selection of the graft source and modification of conditioning regimens, may improve haplo‑HSCT outcomes. Aim. To evaluate the results of haplo‑HSCT in AML patients in first remission, focusing on engraftment rates and the factors influencing them. Materials and methods. Seventy‑three AML patients in first remission who underwent haplo‑HSCT between 2015 and 2024 were included in the study. Engraftment was defined as achieving an absolute neutrophil count of ≥ 0.5 × 109 / L and a leukocyte count of ≥ 1 × 109 / L for three consecutive days and was assessed using cumulative incidence functions with death as a competing event. Results. The engraftment rate was 80.8 % (95 % confidence interval (CI) 69.5–88.3) with a median time of 20 (15–31) days. A higher probability of engraftment was associated with the use of peripheral blood stem cells as the graft source (hazard ratio (HR) 2.62; 95 % CI 1.5–4.58; p 0.001), myeloablative conditioning (HR 2.29; 95 % CI 1.17–4.45; p = 0.015), a higher Cd34+ cell count in the graft (HR 1.17; 95 % CI 1.05–1.31; p = 0.004), pre‑transplant biological therapy (HR 2.28; 95 % CI 1.33–3.91; p = 0.003), and the inclusion of bendamustine in the conditioning regimen (HR 2.32; 95 % CI 1.33–4.03; p = 0.003). Moreover, the use of peripheral blood stem cells, myeloablative conditioning, and bendamustine significantly reduced the time to engraftment (p = 0.016; p = 0.017; and p = 0.033, respectively). An increased level of Cd34+ cells in the graft correlated with faster engraftment (R = –0.34; p = 0.009). The engraftment rate after a second transplantation was 55.6 % (95 % CI 16.9–82.3). Conclusion. Haplo‑HSCT remains an important therapeutic option for AML patients in first remission, although its efficacy is limited by the risk of primary graft failure. The use of peripheral blood stem cells, myeloablative conditioning regimens, and modified protocols incorporating bendamustine enhances the probability of engraftment. Of additional interest is the observed positive effect of preceding venetoclax‑based biological therapy. despite the high risk of transplant‑related mortality, a second transplantation appears to be an optimal strategy in cases of primary graft failure.
- 19 March 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (1) , 114-121
Open AccessHow to reduce the risk of primary engraftment failure after haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia?
Background. Haploidentical hematopoietic stem cell transplantation (haplo‑HSCT) represents an important alternative for patients with acute myeloid leukemia (AML) who lack an HLA‑matched donor. However, the high incidence of primary graft failure remains a significant challenge. Optimizing transplantation strategies, including the selection of the graft source and modification of conditioning regimens, may improve haplo‑HSCT outcomes. Aim. To evaluate the results of haplo‑HSCT in AML patients in first remission, focusing on engraftment rates and the factors influencing them. Materials and methods. Seventy‑three AML patients in first remission who underwent haplo‑HSCT between 2015 and 2024 were included in the study. Engraftment was defined as achieving an absolute neutrophil count of ≥ 0.5 × 109 / L and a leukocyte count of ≥ 1 × 109 / L for three consecutive days and was assessed using cumulative incidence functions with death as a competing event. Results. The engraftment rate was 80.8 % (95 % confidence interval (CI) 69.5–88.3) with a median time of 20 (15–31) days. A higher probability of engraftment was associated with the use of peripheral blood stem cells as the graft source (hazard ratio (HR) 2.62; 95 % CI 1.5–4.58; p 0.001), myeloablative conditioning (HR 2.29; 95 % CI 1.17–4.45; p = 0.015), a higher Cd34+ cell count in the graft (HR 1.17; 95 % CI 1.05–1.31; p = 0.004), pre‑transplant biological therapy (HR 2.28; 95 % CI 1.33–3.91; p = 0.003), and the inclusion of bendamustine in the conditioning regimen (HR 2.32; 95 % CI 1.33–4.03; p = 0.003). Moreover, the use of peripheral blood stem cells, myeloablative conditioning, and bendamustine significantly reduced the time to engraftment (p = 0.016; p = 0.017; and p = 0.033, respectively). An increased level of Cd34+ cells in the graft correlated with faster engraftment (R = –0.34; p = 0.009). The engraftment rate after a second transplantation was 55.6 % (95 % CI 16.9–82.3). Conclusion. Haplo‑HSCT remains an important therapeutic option for AML patients in first remission, although its efficacy is limited by the risk of primary graft failure. The use of peripheral blood stem cells, myeloablative conditioning regimens, and modified protocols incorporating bendamustine enhances the probability of engraftment. Of additional interest is the observed positive effect of preceding venetoclax‑based biological therapy. despite the high risk of transplant‑related mortality, a second transplantation appears to be an optimal strategy in cases of primary graft failure.
- Open Access
- 19 March 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (1) , 55-64
Targeted therapy of newly diagnosed FLT3-mutated acute myeloid leukemia. A single-center ambispective cohort study
Background. FMS‑like tyrosine kinase 3 (FLT3) gene mutations are the most frequently detected genetic aberrations in adult patients with newly diagnosed acute myeloid leukemia (AML), identified in approximately 30 % of patients. The addition of midostaurin, an FLT3 tyrosine kinase inhibitor, to standard therapy and after allogeneic hematopoietic stem cell transplantation (allo‑HSCT) improves overall (OS) and event‑free survival (EFS). Aim. To evaluate the effect of adding midostaurin to standard therapy in adult patients with FLT3‑mutated AML. To evaluate the impact of allo‑HSCT performed in first complete remission on the survival of patients treated in combination with midostaurin. Materials and methods. The study enrolled 276 patients with newly diagnosed AML with FLT3 mutation. 153 of them received combination therapy with midostaurin, 123 – first‑line therapy without FLT3 inhibitors. In the combination therapy group allo‑HSCT in first complete remission was performed in 35 (22.9 %) patients. Results. The response rate was higher in the combination therapy group and was 84 % versus 66 % in the control group (p 0.01). with a median follow‑up of 19 (2–130) months, the median OS was not achieved in both groups. The 18‑month OS was 60 % (95 % confidence interval (CI) 50–69) in the midostaurin group and 53 % (95 % CI 43–61) without it (p = 0.12). Median EFS was 11.6 months (95 % CI 9.1–13.8) and 6.7 months (95 % CI 4.2–10.2) respectively (p = 0.046). The 18‑month EFS was 33 % (95 % CI 24–42) and 31 % (95 % CI 23–40). In multivariate analysis, factors associated with worse EFS were older age and FLT3 internal tandem duplication. Age, leukocytosis at the time of diagnosis, and the presence of unfavorable cytogenetic abnormalities had a negative effect on EFS. Midostaurin therapy was associated with EFS improvement. In a landmark analysis with a 6‑month time point, OS was 89 % (95 % CI 69–96) in the allo‑HSCT group versus 38 % without it (95 % CI 20–55) (p = 0.002). EFS was 75 % (95 % CI 50–88) and 13 % (95 % CI 5–26), respectively (p 0.001). Conclusion. The addition of midostaurin to standard treatment contributes to an increased response rate and improved survival in patients with FLT3‑mutated AML. Allo‑HSCT in first complete remission remains the preferred option for remission consolidation in patients treated with tyrosine kinase inhibitors.
- 19 March 2025
- Published by Publishing House ABV Press in Oncohematology
- Vol. 20 (1) , 55-64
Open AccessTargeted therapy of newly diagnosed FLT3-mutated acute myeloid leukemia. A single-center ambispective cohort study
Background. FMS‑like tyrosine kinase 3 (FLT3) gene mutations are the most frequently detected genetic aberrations in adult patients with newly diagnosed acute myeloid leukemia (AML), identified in approximately 30 % of patients. The addition of midostaurin, an FLT3 tyrosine kinase inhibitor, to standard therapy and after allogeneic hematopoietic stem cell transplantation (allo‑HSCT) improves overall (OS) and event‑free survival (EFS). Aim. To evaluate the effect of adding midostaurin to standard therapy in adult patients with FLT3‑mutated AML. To evaluate the impact of allo‑HSCT performed in first complete remission on the survival of patients treated in combination with midostaurin. Materials and methods. The study enrolled 276 patients with newly diagnosed AML with FLT3 mutation. 153 of them received combination therapy with midostaurin, 123 – first‑line therapy without FLT3 inhibitors. In the combination therapy group allo‑HSCT in first complete remission was performed in 35 (22.9 %) patients. Results. The response rate was higher in the combination therapy group and was 84 % versus 66 % in the control group (p 0.01). with a median follow‑up of 19 (2–130) months, the median OS was not achieved in both groups. The 18‑month OS was 60 % (95 % confidence interval (CI) 50–69) in the midostaurin group and 53 % (95 % CI 43–61) without it (p = 0.12). Median EFS was 11.6 months (95 % CI 9.1–13.8) and 6.7 months (95 % CI 4.2–10.2) respectively (p = 0.046). The 18‑month EFS was 33 % (95 % CI 24–42) and 31 % (95 % CI 23–40). In multivariate analysis, factors associated with worse EFS were older age and FLT3 internal tandem duplication. Age, leukocytosis at the time of diagnosis, and the presence of unfavorable cytogenetic abnormalities had a negative effect on EFS. Midostaurin therapy was associated with EFS improvement. In a landmark analysis with a 6‑month time point, OS was 89 % (95 % CI 69–96) in the allo‑HSCT group versus 38 % without it (95 % CI 20–55) (p = 0.002). EFS was 75 % (95 % CI 50–88) and 13 % (95 % CI 5–26), respectively (p 0.001). Conclusion. The addition of midostaurin to standard treatment contributes to an increased response rate and improved survival in patients with FLT3‑mutated AML. Allo‑HSCT in first complete remission remains the preferred option for remission consolidation in patients treated with tyrosine kinase inhibitors.
- Open Access
- 1 January 2025
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 18 (1) , 73-85
Theoretical and Practical Aspects of Studying the Fractions of BAALC-Expressing Hematopoietic Stem Cells in Acute Myeloid Leukemia Patients with FLT3 Mutations
AIM. To study the fractions of BAALC-expressing (BAALC-e) leukemic hematopoietic stem cells (LHSCs) in acute myeloid leukemia (AML) patients with isolated mutations in the FLT3 gene as well as their combinations with the mutations in the NPM1 gene. MATERIALS & METHODS. The study enrolled adult AML patients with the common element of having isolated FLT3 mutations in the genome (n = 25). The control group (n = 21) consisted of AML patients with mutations in both FLT3 and NPM1. The patients (n = 46) were aged 18–84 years (median 52 years), there were 26 women and 20 men. Non-random chromosomal aberrations, including those of a complex nature (≥ 3 lesions per metaphase), were identified in 13 patients with isolated FLT3 mutation and in 1 patient with both FLT3 and NPM1 mutations. Quantitative real-time PCR was used to measure the level of BAALC, WT1, and EVI1 expressions by the cells in bone marrow aspirate. Thresholds for distinguishing between high and low levels of BAALC and EVI1 expression were considered to be 31 % and 10 %, respectively, and the thresholds for WT1 and FLT3 allele ratio were 250 copies/104 ABL1 copies and 0.5, respectively. РЕЗУЛЬТАТЫ. An increased BAALC expression level roughly reflecting the fraction size of BAALC-e LHSCs was detected in 20/25 (80 %) patients with isolated FLT3 mutations. This was observed together with an increased level of WT1 (n = 22) and EVI1 (n = 7) expression. In all patients with both FLT3 and NPM1 mutations (control group, n = 21), the BAALC and EVI1 expression levels were below the threshold, which did not affect WT1 expression. This observation suggests to question the random nature of the identified decrease of BAALC and EVI1 expressions, which can be hypothetically accounted for by a low count of CD34-positive LHSCs in the bone marrow of AML patients with NPM1 mutations. Serial measurements of these molecular parameters under therapy for AML with FLT3 +/– NPM1 mutations show the feasibility of their use in assessing the therapy efficacy or the need for its correction, if required. CONCLUSION. The data presented in this paper clearly indicate that clinical trials need to intensively apply serial analysis of the fractions of BAALC-expressing leukemic HSCs in AML patients with FLT3 mutations. This approach allows for better molecular monitoring of the therapy efficacy for this challenging category of AML patients.
- 1 January 2025
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 18 (1) , 73-85
Open AccessTheoretical and Practical Aspects of Studying the Fractions of BAALC-Expressing Hematopoietic Stem Cells in Acute Myeloid Leukemia Patients with FLT3 Mutations
AIM. To study the fractions of BAALC-expressing (BAALC-e) leukemic hematopoietic stem cells (LHSCs) in acute myeloid leukemia (AML) patients with isolated mutations in the FLT3 gene as well as their combinations with the mutations in the NPM1 gene. MATERIALS & METHODS. The study enrolled adult AML patients with the common element of having isolated FLT3 mutations in the genome (n = 25). The control group (n = 21) consisted of AML patients with mutations in both FLT3 and NPM1. The patients (n = 46) were aged 18–84 years (median 52 years), there were 26 women and 20 men. Non-random chromosomal aberrations, including those of a complex nature (≥ 3 lesions per metaphase), were identified in 13 patients with isolated FLT3 mutation and in 1 patient with both FLT3 and NPM1 mutations. Quantitative real-time PCR was used to measure the level of BAALC, WT1, and EVI1 expressions by the cells in bone marrow aspirate. Thresholds for distinguishing between high and low levels of BAALC and EVI1 expression were considered to be 31 % and 10 %, respectively, and the thresholds for WT1 and FLT3 allele ratio were 250 copies/104 ABL1 copies and 0.5, respectively. РЕЗУЛЬТАТЫ. An increased BAALC expression level roughly reflecting the fraction size of BAALC-e LHSCs was detected in 20/25 (80 %) patients with isolated FLT3 mutations. This was observed together with an increased level of WT1 (n = 22) and EVI1 (n = 7) expression. In all patients with both FLT3 and NPM1 mutations (control group, n = 21), the BAALC and EVI1 expression levels were below the threshold, which did not affect WT1 expression. This observation suggests to question the random nature of the identified decrease of BAALC and EVI1 expressions, which can be hypothetically accounted for by a low count of CD34-positive LHSCs in the bone marrow of AML patients with NPM1 mutations. Serial measurements of these molecular parameters under therapy for AML with FLT3 +/– NPM1 mutations show the feasibility of their use in assessing the therapy efficacy or the need for its correction, if required. CONCLUSION. The data presented in this paper clearly indicate that clinical trials need to intensively apply serial analysis of the fractions of BAALC-expressing leukemic HSCs in AML patients with FLT3 mutations. This approach allows for better molecular monitoring of the therapy efficacy for this challenging category of AML patients.
- 17 May 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (5) , e15331
Impact of prior COVID‐19 infection on allogeneic hematopoietic stem cell transplantation outcomes
There are limited data on outcomes of allogeneic hematopoietic stem cell transplantation (allo‐HSCT) in recipients with prior COVID‐19 infection. This single‐center retrospective study included 54 adult patients who received allo‐HSCT from July 2020 to September 2021 after previous COVID‐19 infection and 122 control group patients without a history of COVID‐19 who underwent HSCT during the same period, with a median follow‐up of 17 months. Median time from COVID‐19 to allo‐HSCT was 211 days. The incidence of main complications in the post‐transplant period was not significantly different between the two groups: deep vein thrombosis (p = .85), TMA (p = .8), VOD (p = .25), bloodstream infections (p = .21), pneumonia of any etiology (p = .41), viral infections (p = .85), invasive fungal disease (p = .08). The 2‐year non‐relapse mortality, relapse incidence, overall survival, and progression‐free survival also were comparable in the study and the control groups: 22% (95% CI 10.5–36.2) versus 26.3% (95% CI 18.7–34.6) p = .4; 15.6% (95% CI 7.3–26.9) versus 23.6% (95% CI 16.0–32.3) p = .39; 67.9% (95% CI 50.4–80.3) versus 59.8% (95% CI 50.2–68.1) p = .24 and 62.3% (95% CI 45.5–75.3) versus 49.9% (95% CI 40.0–59.1) p = .18, respectively. The history of previous COVID‐19 infection did not affect the results of allo‐HSCT.
- 17 May 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (5) , e15331
Impact of prior COVID‐19 infection on allogeneic hematopoietic stem cell transplantation outcomes
There are limited data on outcomes of allogeneic hematopoietic stem cell transplantation (allo‐HSCT) in recipients with prior COVID‐19 infection. This single‐center retrospective study included 54 adult patients who received allo‐HSCT from July 2020 to September 2021 after previous COVID‐19 infection and 122 control group patients without a history of COVID‐19 who underwent HSCT during the same period, with a median follow‐up of 17 months. Median time from COVID‐19 to allo‐HSCT was 211 days. The incidence of main complications in the post‐transplant period was not significantly different between the two groups: deep vein thrombosis (p = .85), TMA (p = .8), VOD (p = .25), bloodstream infections (p = .21), pneumonia of any etiology (p = .41), viral infections (p = .85), invasive fungal disease (p = .08). The 2‐year non‐relapse mortality, relapse incidence, overall survival, and progression‐free survival also were comparable in the study and the control groups: 22% (95% CI 10.5–36.2) versus 26.3% (95% CI 18.7–34.6) p = .4; 15.6% (95% CI 7.3–26.9) versus 23.6% (95% CI 16.0–32.3) p = .39; 67.9% (95% CI 50.4–80.3) versus 59.8% (95% CI 50.2–68.1) p = .24 and 62.3% (95% CI 45.5–75.3) versus 49.9% (95% CI 40.0–59.1) p = .18, respectively. The history of previous COVID‐19 infection did not affect the results of allo‐HSCT.
- Open Access
Trends in Outcome of Hematopoietic Stem Cell Transplantation: 5000 Transplantations and 30 Years of Single-Center Experience
In this single-center analysis, we evaluated the trends in 5185 hematopoietic cell transplantations performed between 1990 and 2022. The study group comprised 3237 allogeneic (alloHCT) and 1948 autologous (autoHCT) hematopoietic cell transplantations. In the multivariate analysis, there was an improvement in event-free-survival (EFS) after autoHCT (HR 0.6, 95% CI 0.4–0.7, p < 0.0001) due to reduced cumulative incidence of relapse in the last five years (56% in 2010–2014 vs. 38% in 2015–2022). An improvement in EFS after alloHCT over time was observed (HR 0.33, 95% CI 0.23–0.48, p < 0.0001), which was due to reduced non-relapse mortality. No difference in cumulative relapse incidence was observed over the last decade for allografted patients. Survival after autoHCT improved in Hodgkin’s disease (HR 0.1, 95% CI 0.1–0.3), multiple myeloma (HR 0.4, 95% CI 0.2–0.7) and solid tumors (HR 0.2, 95% CI 0.2–0.4), while after alloHCT, improvement was observed in acute myeloid leukemia (HR 0.3, 95% CI 0.1–0.5), acute lymphoblastic leukemia (HR 0.2, 95% CI 0.1–0.5), Hodgkin’s disease (HR 0.1, 95% CI 0.0–0.4), non-Hodgkin’s lymphomas and chronic lymphocytic leukemia (HR 0.2, 95% CI 0.0–0.6), inborn diseases (HR 0.2, 95% CI 0.2–0.4) and acquired aplastic anemia with matched related donors and matched unrelated donors (HR 0.3, 95% CI 0.2–0.8).
Open AccessTrends in Outcome of Hematopoietic Stem Cell Transplantation: 5000 Transplantations and 30 Years of Single-Center Experience
In this single-center analysis, we evaluated the trends in 5185 hematopoietic cell transplantations performed between 1990 and 2022. The study group comprised 3237 allogeneic (alloHCT) and 1948 autologous (autoHCT) hematopoietic cell transplantations. In the multivariate analysis, there was an improvement in event-free-survival (EFS) after autoHCT (HR 0.6, 95% CI 0.4–0.7, p < 0.0001) due to reduced cumulative incidence of relapse in the last five years (56% in 2010–2014 vs. 38% in 2015–2022). An improvement in EFS after alloHCT over time was observed (HR 0.33, 95% CI 0.23–0.48, p < 0.0001), which was due to reduced non-relapse mortality. No difference in cumulative relapse incidence was observed over the last decade for allografted patients. Survival after autoHCT improved in Hodgkin’s disease (HR 0.1, 95% CI 0.1–0.3), multiple myeloma (HR 0.4, 95% CI 0.2–0.7) and solid tumors (HR 0.2, 95% CI 0.2–0.4), while after alloHCT, improvement was observed in acute myeloid leukemia (HR 0.3, 95% CI 0.1–0.5), acute lymphoblastic leukemia (HR 0.2, 95% CI 0.1–0.5), Hodgkin’s disease (HR 0.1, 95% CI 0.0–0.4), non-Hodgkin’s lymphomas and chronic lymphocytic leukemia (HR 0.2, 95% CI 0.0–0.6), inborn diseases (HR 0.2, 95% CI 0.2–0.4) and acquired aplastic anemia with matched related donors and matched unrelated donors (HR 0.3, 95% CI 0.2–0.8).
- Open Access
- 30 August 2023
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 23, S151
POSTER: ALL-329 Ph-Negative Acute Lymphoblastic Leukemia (ALL) in Adolescent and Young Adults: Long-Term Outcomes After Treatment According to the Adult Strategy RALL Protocol
- 30 August 2023
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 23, S151
Open AccessPOSTER: ALL-329 Ph-Negative Acute Lymphoblastic Leukemia (ALL) in Adolescent and Young Adults: Long-Term Outcomes After Treatment According to the Adult Strategy RALL Protocol